Krystal Biotech, Inc. (KRYS) Earnings History
Profitable10 years of earnings data (2016–2025) · Positive TTM net income
Loading earnings history...
Krystal Biotech, Inc. (KRYS) Earnings Overview
As of June 22, 2026, Krystal Biotech, Inc. (KRYS) reported trailing twelve-month net income of $225M, reflecting +128.0% year-over-year growth. The company earned $7.38 per diluted share over the past four quarters, with a net profit margin of 52.6%.
Looking at the long-term picture, KRYS's historical earnings data spans multiple years. The company achieved its highest annual net income of $205M in fiscal 2025, representing a new all-time high.
Krystal Biotech, Inc. maintains industry-leading profitability with a gross margin of 92.6%, operating margin of 41.5%, and net margin of 52.6%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RCKT (-$209M net income), RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), KRYS has comparable earnings metrics. Compare KRYS vs RCKT →
KRYS Earnings vs Peers
Earnings metrics vs comparable public companies
KRYS Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $205M | +129.7% | $161M | $6.84 | 52.6% | 41.5% |
| 2024 | $89M | +715.6% | $66M | $3.00 | 30.7% | 22.6% |
| 2023 | $11M | +107.8% | -$110M | $0.39 | 21.6% | -216.4% |
| 2022 | -$140M | -101.2% | -$145M | $-5.49 | - | - |
| 2021 | -$70M | -116.3% | -$68M | $-3.13 | - | - |
| 2020 | -$32M | -68.5% | -$33M | $-1.71 | - | - |
| 2019 | -$19M | -75.3% | -$22M | $-1.20 | - | - |
| 2018 | -$11M | -37.5% | -$12M | $-0.97 | -1060.3% | -1160.3% |
| 2017 | -$8M | -588.7% | -$5M | $-1.48 | - | - |
| 2016 | -$1M | - | -$1M | $-0.27 | - | - |
Download Data
Export KRYS earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into KRYS consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KRYS — Frequently Asked Questions
Quick answers to the most common questions about buying KRYS stock.
What is KRYS earnings per share (EPS)?
KRYS trailing twelve-month (TTM) diluted EPS is $7.38, reflecting +128.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Krystal Biotech, Inc.'s net income?
Krystal Biotech, Inc. (KRYS) trailing twelve-month net income is $225M as of 2025. Earnings grew +128.0% year-over-year. Krystal Biotech, Inc. has been profitable for 3 consecutive years.
Is KRYS profitable?
Yes, KRYS is profitable with a TTM net income of $225M and a net profit margin of +52.6%. Krystal Biotech, Inc. has generated profits for 3 consecutive years.
What is KRYS's earnings growth rate?
KRYS compound annual EPS growth rates (CAGR): 1-Year: +128.0%, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are KRYS's profit margins?
Krystal Biotech, Inc. net profit margin is +52.6%, operating margin is +41.5%, and gross margin is +92.6%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +18.9%.
Is KRYS growing earnings?
Yes, KRYS earnings are accelerating — EPS growth of +128.0% exceeds the 5-year CAGR of N/A. TTM net income reached $225M. Earnings momentum is strengthening.
What was KRYS's best earnings year?
Krystal Biotech, Inc.'s highest annual net income on record is $205M, achieved in fiscal year 2025. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were KRYS's earnings last quarter?
KRYS's most recent reported quarter was Q1 2026. Net income was $56M with diluted EPS of $1.83. For a full breakdown of all quarters, see the quarterly earnings table on this page.